CDEK
← All organizations

Horizon Therapeutics, LLC

For profitContributed to NMEWebsite ↗

Also known as: HORIZON THERAP | Horizon Therapeutics | HORIZON THERAPEUTICS IRELAND | Horizon Therapeutics Ireland DAC | HORIZON THERAPEUTICS IRELAND DAC | Horizon Therapeutics, LLC | Horizon Therapeutics USA, Inc. | HORIZON THERAP US

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Oct 1, 2010

First marketed drug

Nov 1, 2006

First NDA

Jan 21, 2020

Last known activity

Feb 25, 2024

Acquired by Amgen on Dec 12, 2022

Timeline

1990s

  1. Feb 25, 1999

    interferon gamma-1b— NDA Organization

2000s

  1. Nov 1, 2006

    Horizon Therapeutics, LLC— Founded

2010s

  1. Feb 1, 2013

    glycerol phenylbutyrate— Marketing Organization

  2. Feb 1, 2013

    glycerol phenylbutyrate— NDA Secondary Org

2020s

  1. Feb 1, 2021

    Viela Bio— Acquired

  2. Dec 12, 2022

    Amgen— Acquired By

Drugs by trial phase (14 distinct, 33 trials)

Phase 3 (0 own, 1 via acquisition)

Phase 2 (2 own, 2 via acquisition)

Phase 1 (1 own, 2 via acquisition)

Indications

Studied for

Marketed drugs (6)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (41)

Details

Founded
Brisbane, CA, US Nov 1, 2006
First NDA
Jan 21, 2020
Last known activity
Feb 25, 2024

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Breakthrough therapy